Latest Market Research Updates: October 2019

Medical Image Analysis Software Market Is Estimated To Reach $4.51 Billion By 2024

The global medical image analysis software market size is expected to reach USD 4.51 billion by 2024, according to a new report by Grand View Research, Inc., registering an 8.1% CAGR during the forecast period. Increasing incidence of chronic diseases creates demand for effective diagnostics solutions, which spurs demand for medical image analysis software. High growth of the industry is majorly attributed to increase in usage and uptake of image analysis solutions for diagnosis.

In addition, shifting focus to provide enhanced care has led to incorporation of various computer aided diagnosis systems, which is further contributing toward growth. Introduction of technologically advanced products such as 3D/4D platforms and multimodality imaging platforms is also presumed to augment growth over the coming years.

Various benefits such as flexibility and high-resolution images, along with convenient use of multi-modal integrated workflows, are expected to bolster demand and increase product penetration throughout the forecast period. Stand-alone platforms are anticipated to witness steady growth. These platforms are user-friendly and cost less as compared to integrated solutions. These solutions offer more details and features and are used by researchers, allowing them to share and access research data and analyses, thereby enhancing their ability to diagnose, research, monitor, and treat disorders. For instance, GE healthcare’s ViewPoint 6 (for MFM) is a standalone software designed for dedicated ultrasound reporting and image management.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/medical-image-analysis-software-market

Further key findings from the report suggest:

By type, the integrated medical image analysis software segment is anticipated to expand at a CAGR of 7.8% from 2016 to 2024
On the basis of modality, the ultrasound segment is projected to ascend at a revenue-based CAGR of 10.5% over the forecast period
The orthopedic segment dominated the global market by application, accounting for over 40.0% share in 2015
By end use, hospitals held the largest revenue share owing to increasing adoption of these systems for medical imaging in diagnosis of various diseases
Asia Pacific is expected to show significant growth owing to presence of unmet clinical needs
The global market is fragmented in nature. Companies are witness fierce competition as the industry is technology driven
Strategies implemented by key players include collaborative agreements, new product launches, and geographical expansion.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com

Diabetic Retinopathy Market Is Poised To Reach $10.08 Billion By 2025

The global diabetic retinopathy market is anticipated to reach USD 10.08 billion by 2025, according to a new report by Grand View Research, Inc. Rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are among the key factors anticipated to bolster market growth over the forecast period.

Diabetes is amongst the leading cause of blindness in people. Blindness is caused due to leaking or rupturing of retinal blood vessels, which may be permanent or temporary in nature depending on the disease-stage. According to the Department of Assistive and Rehabilitative Services (DARS), Texas, around 78.0% cases of diabetic retinopathy were reported in 2013 that may eventually lead to loss of vision. In addition, as per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was amongst the leading causes of blindness in UK in 2017. Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth.

Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the diabetic retinopathy market over the forecast period. According to the Population Reference Bureau report titled "Aging in the United States”, the number of people in the U.S., aged 65 years and over were projected to increase from around 46 million in 2016 to over 98 million by 2060.

To request a sample copy or view summary of this report, click the link below:

https://www.grandviewresearch.com/industry-analysis/diabetic-retinopathy-market

Further Key Findings From the Study Suggest:

Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2016. Presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.
Anti-VEGF segment accounted for the largest share, by management, in 2016. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
Asia Pacific market is expected to grow with the highest CAGR over the forecast period. Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.
Major players of the market include Bayer Healthcare, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc, ThromboGenics NV, Sirnaomics, Inc., Genentech, Glycadia Pharmaceuticals, Alimera Sciences, and Ampio Pharmaceuticals, BCN Peptides, and Kowa Group.

About Grand View Research

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com

Diabetes Devices Market Is Expected To Surpass Mark Of $35.5 Billion By 2024

The global diabetes devices market size is expected to reach USD 35.5 billion by 2024, according to a new report by Grand View Research, Inc. The market is projected to expand at a CAGR of 7.0% during the forecast period. Growing cases of diabetes, due to obesity, sedentary and unhealthy lifestyles, and several other factors, is expected to drive demand for diabetes devices over the next few years.

Obesity is believed to be one of the foremost factors leading to diabetes in individuals. According to WHO, in 2014, over 1.9 billion people were identified to be overweight, of which, around 600 million people were obese.

Some of the key companies in the global diabetes devices market are Medtronic PLC, Sanofi S.A., Bayer Healthcare AG, Becton, Dickinson and Company, Novo Nordisk A/S, Abbott Laboratories, F. Hoffman-La Roche AG, and Johnson & Johnson.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/diabetes-devices-market

Further key findings from the study suggest:

Constantly rising target population base is the primary factor driving market growth
Test strips capturedthe largest share in the monitoring and diagnostics device segment while insulin pens accounted for the largest revenue share among insulin delivery devices in 2016. This can be attributed to rapid adoption of these user-friendly, quick, and accurate devices for homecare use
North America is leading the regional market, followed by Europe. Advanced healthcare infrastructure and availability of technologically advanced products have driven the regional market
Key players in the market include Medtronic PLC, Sanofi S.A., Bayer Healthcare AG, Becton Dickinson and Company, Novo Nordisk A/S, Abbott Laboratories, F. Hoffman-La Roche AG and Johnson & Johnson.

About Grand View Research

Dental 3D Printing Market Is Poised To Reach $9.78 Billion By 2025

The global dental 3D printing market size is expected to reach USD 9.7 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 29.3% during the forecast period. Rising prevalence of tooth conditions is resulting in increase in tooth replacement surgeries. This, coupled with growing global geriatric population and surging demand for customized dental 3D printing solutions, is providing a significant push to the market. Increasing collaborations by key players and growing awareness among consumers are also likely to help the market gain tremendous traction over the coming years.

Since aged people are more susceptible to oral health issues, rising geriatric population worldwide is translating into upswing in cases of tooth replacement surgeries. As per the findings of the National Institute of Dental and Craniofacial Research, the average teeth remaining of geriatric population (aged 65 years and above) is 18.9. Thus, rise in their population is creating a highly lucrative market for dental 3D printing. Furthermore, innovative and low cost technologies are set to shape the future of the market and increase in usage rate of dental 3D printed products over the forecast period.

To request a sample copy or view summary of this report, click the link below:

https://www.grandviewresearch.com/industry-analysis/dental-3d-printing-market

Further key findings from the report suggest:

In terms of revenue, the selective laser sintering segment is projected to expand at a CAGR of over 29.0% during the forecast period. This segment will be the leading revenue contributor in the market throughout the forecast horizon owing to the benefits offered such as its chemical resistance, biocompatibility, and excellent surface finishing ability
In 2025, North America dominated the market with a market share of just over 38.0%. It is expected to witness steady growth over the same period owing to supportive government initiatives and appropriate funding
Some of the key companies present in the market are SLM Solutions; 3D Systems; ; Roland DG Corporation; Stratasys; Straumann AG GroupDentsPly Sirona Inc.; Prodways Group; Renishaw Inc.; EnvisionTEC; and FormLabs Inc.

About Grand View Research

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com

Coronary Stents Market Is Poised To Reach $15.18 Billion By 2024

The global coronary stents market is expected to reach USD 15.18 billion by 2024, according to a new report by Grand View Research, Inc. Rising prevalence of coronary artery diseases, supportive government reforms and increasing awareness are contributing factors for lucrative growth of coronary stents

The latest treatments available in cardiac care are expected to increase the life span of the elderly population subset. This demographic is characterized with low immunity levels and are prone to chronic diseases including CVDs. Thus, increasing geriatric population is thereby considered as a high impact rendering driver for the growth of this industry over the forecast period.

The coronary stent market is driven by reimbursement coverage provided by the general public Center for Medicare & Medicaid Services (CMS) and private payers. The coverage is availed under national coverage determination for carotid artery stenting, including products and service provider. The providers require completing certain conditions for coverage, all facilities to be certified by CMS to perform CAS procedures.

Reimbursement of medical devices is limited to the developed regions of Asia Pacific. For instance, Japan’s National Health Insurance system provides reimbursement for all medical devices. However, some countries in the Asia Pacific region have no scope for reimbursement and the patients themselves incur the expenses while the unprivileged ones often forego treatment, thus restraining the growth of this vertical in certain countries.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/coronary-stents-industry

Further key findings from the study suggest:

DES held lucrative share in 2015. Avoidance of complications, ease of procedures and comfort to the patient are factors responsible for increased usage rate.
BVS are anticipated to growth exponential over the forecast period due to the added advantages such as restoring vasomotor function, and fewer complications offered by the product.
North America held substantial share in global coronary stents market. Sophisticated healthcare system, well planned reimbursement program, high healthcare expenditure and large pool of target population are responsible for the region’s substantial share.
Asia Pacific is anticipated to exhibit lucrative growth over the forecast period. Economic developments and government reforms especially in countries like India and China are supporting the growth of this region.

About Grand View Research

3D Bioprinting Market Is Poised To Reach $4.1 Billion By 2026

The global 3D bioprinting market size is expected to reach USD 4.1 billion by 2026 registering a CAGR of 19.5%, according to a new report by Grand View Research, Inc. Growing usage of 3D printing in cosmetic surgeries and innovations in the 3D bioprinting are expected to propel the market growth over the forecast period. The technology is commonly used to print prosthetics and dental accessories, medical devices, and bone implants. The medical application segment is projected to expand at a significant pace, as the technology has the potential to reduce the drug development costs.

For instance, in March 2016, a U.S.-based specialty pharmaceutical firm became the world’s first company to receive approval from the FDA for Spritam, a 3D bioprinted drug. Rising cases of chronic diseases and limited number of organ donors along with rising compliance in the drug discovery and development are also expected to boost market growth. Moreover, technological advancements, increased R&D investments, and growing geriatric population bases across the globe will drive the market further.

Access Full Insights: https://www.grandviewresearch.com/industry-analysis/3d-bioprinting-market

Further key findings from the study suggest:

The syringe-based bioprinting emerged as the largest segment with market share of over 36.10% in 2018 and it is expected to register a CAGR of 18.9% over the forecast period
Dental segment is expected to register the fastest growth due to increasing usage of 3D printing technologies in dental prosthetics
North America led the global market with in 2018 owing to the presence of well-established companies and heavy research funding from the federal government
Some of the companies in the global 3D bioprinting market include Organovo Holding, Inc.; BioBots; Cyfuse Biomedical K.K.; Luxexcel Group BV; TeVido BioDevices, LLC; 3Dynamics Systems Ltd.; Aspect Biosystems; Stratasys Ltd.; Materialise N.V.; EnvisionTEC; Voxeljet AG; Oceanz; and Bio3D Technologies Pte. Ltd.

About Grand View Research

Stem Cell Market Total Revenue Would Be $15.63 Billion By 2025

The global stem cell market size is expected to reach USD 15.63 billion by 2025, at a CAGR of 8.8% during the forecast period, according to a new report by Grand View Research, Inc. Amplifying research studies targeted at widening the utility scope of stem cell products is anticipated to drive the growth. These research projects are set to offer new opportunities for implementation of several clinical applications of stem cells. Thus, extensive research on exploring varied applications of stem cells would impact treatment options that aid in disease-modification.

In addition, collaborations targeted at achieving robust manufacturing of high-quality differentiated cells is expected open up new avenues of market expansion over the forecast period. Rapid transition from conventional treatment methods to regenerative medicine has been observed over the past few years. Regenerative medicine is set to become the new prototype of treatment in human health having the potential to address unmet medical needs across the globe. Integration of biologics, chemical compounds, materials, and devices is witnessed in stem cell therapeutics making it an interdisciplinary field.

Moreover, rising recognition of cellular therapies as an emerging revolutionary advancement has been witnessed in the healthcare industry in recent years. Business expansion is adopted by companies aiming at strengthening their portfolio regarding cellular therapy. This is expected to improve detailed understanding and future potential of stem cells for the of patients suffering from Parkinson's disease, diabetes, injuries associated with spinal cord, and other neurodegenerative disorders.

Further, a maturing and strongly diversified clinical pipeline is expected to contribute to the growth of stem cell market. Availability of latest data during the mid and late stage of the regenerative medicine clinical trials and increase in the product approvals regarding the same is expected to drive the market.

Adult stem cells displayed highest contribution in the market and is expected to maintain its dominance over the forecast period. Factors such as minimal ethical issues, lower rejection rates, and long-term renewal property associated with stem cells utility has contributed to the dominance of this segment. Moreover, the characteristic property of these cells to regenerate into malignant cells is anticipated to support the estimated share.

Scientists at Michigan State University revealed novel type of cells, named induced XEN cells, originated from a cellular trash pile in March 2016. The conclusions drawn from this research study is expected to drive emerging regenerative medicine treatment methods. In January 2019, research professionals at the University of Freiburg carried out research on the potential of mesenchymal stems cells in repairing damaged organs. This is further anticipated to boost research as well as sales in the market throughout the study period.

Access Full Insights: https://www.grandviewresearch.com/industry-analysis/stem-cells-market

Further key findings from the report suggest:

Based on application regenerative medicine is estimated to hold a substantial market share in terms of revenue over the forecast period, owing to rise in emerging pipeline projects
Progress of acquisition technology is expected to gain momentum during the forecast period owing to the rising research projects that demand the use of harvesting techniques
Amongst the type of therapies used, autologous therapy accounted for the largest share of the stem cell market
Likelihood of getting new infections is less in autologous cell-based therapy, consequently enhancing its adoption
R&D activities carried out on large scale and huge funds granted by funding bodies to advance cellular research in U.S. have made North America the dominant region in the global market
Vast research studies taking place in Singapore and Japan is anticipated to propel the Asia Pacific market in the forthcoming years
Osiris Therapeutics Inc.; Celgene Corporation; BIOTIME, INC.; Cynata; Advanced Cell Technology Inc.; and STEMCELL Technologies Inc.; are some of the key market players
The companies are undergoing strategic partnership to enhance their product line. They are keen on seeking investments from overseas organizations along with adopting partnership strategies with pharmaceutical organizations, which is set to fuel the market growth.

About Grand View Research

Biotechnology Market Is Estimated To Generate Revenue Of $727.1 Billion By 2025

The global biotechnology market is expected to reach USD 727.1 billion by 2025, according to a new report by Grand View Research, Inc. The emergence of certain key themes in the biotechnology market is expected to drive growth in this industry to a lucrative extent.

These key themes include regenerative medicine and genetics in diagnostics. Presence of a plethora of companies focusing on the development of regenerative therapies is anticipated to drive sector growth through to 2025. Technological advancements pertaining to the penetration of artificial intelligence in this industry is expected to fuel progress with potential avenues. The companies are engaged in unleashing machine learning in order to understand individual cancer cases, while recommending clinical trials.

Supportive government (and its allied agencies) policies related to synthetic biology is a major growth impacting driver in this sector. Developed economies such as UK and the U.S. are critically monitoring and funding synthetic biology R&D initiatives. For example, in 2010, a six months’ review of synthetic biology headed by a panel of expert scientists was enforced by the U.S. President and subsequently conducted a hearing of the Energy and Commerce Committee exclusively concerning synthetic biology.

Access Full Insights: http://www.grandviewresearch.com/industry-analysis/biotechnology-market

Further key findings from the report suggest:

Owing to technological advancements and widespread application of this field in various aspects of healthcare, the health segment is expected to exhibit strong progress in the forecast period
Continuous introduction of new biotechnological products to cater to healthcare entities that are involved in diagnosis, prognosis and biopharmaceutical development is estimated to propel the market
Decreasing costs and rise in number of services in this segment are expected to drive segment with lucrative avenues
North American pharmaceutical and biotech companies have experienced great success in the recent years resulting in larger share
Introduction of technologically advanced products and presence of various biotechnology based programs such as the UC Davis Biotechnology Program, the University of California Biotechnology Research and Education Program are attributive to drive the growth of sector in the coming years
Asia Pacific market is anticipated to grow at the most lucrative pace due to changing health care infrastructure in this region which drives the demand for these products
Strong governmental support and recruitment of highly trained Chinese scientists with the support of their administration has made it possible for China to speedily build up capacity in area of regenerative medicine
Key players operating include Gilead, Celgene, Abbott, Novo Nordisk A/S,Novartis AG, Sanofi Aventis, and Lonza

About Grand View Research

Genomics Market Is Projected To Reach $27.61 Billion By 2025

The global genomics market size is expected to reach USD 27.61 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.6% during the forecast period. The past decades have witnessed significant changes in disease management processes due to simultaneous advancements in genomics and personalized medicine. There has been a gradual growth in the usage of genomic studies in clinical practices, which is reflected by the growing trend of targeted therapies.

Results from genomic studies enable a better understanding of diseases and the underlying mechanisms for researchers, physicians, and consumers. This facilitates evidence-based decision-making, and hence, helps improve personalized treatment regime. In addition, technological advancements in data analysis tools have motivated healthcare community to create precision-based therapies from surplus, available DNA data.

Ability of the medical community to make use of the available genomic information in personalized medicine is anticipated to significantly impact the genomics market. Furthermore, plummeting cost of sequencing has enabled the whole genome sequencing at very less price. Scientists are combining the sequencing generated data with diagnostics which has proven its effectiveness in enhancing personalized treatment landscape.

The companies are involved in strategic alliances with global as well as local entities to boost their revenue generation and enhance their market share. For instance, in March 2017, Foundation Medicine collaborated with Bristol-Myers Squibb Company, as a result of which Bristol-Myers Squibb could deploy Foundation Medicine’s molecular information solutions and comprehensive genomic profiling for identification of predictive biomarkers, such as Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB), to accelerate its immunotherapy clinical trials.

NGS-based services held a major market share in the services segment due to its rapid adoption of whole genome sequencing and application of sequence databases for disease screening and prognosis. The demand would remain strong with the expansion of the customer base from limited to academic and research centers to CROs, biotech and pharma players. As patients are focusing on their health, Direct-To-Consumer (DTC) laboratory testing is increasingly being employed. DTC genetic tests enable consumers to access information about their genetics without necessarily including healthcare professionals in the process.

Access Full Insights: https://www.grandviewresearch.com/industry-analysis/genomics-market

Further key findings from the report suggest:

High demand in terms of volume coupled with the high cost of specific reagents contribute to substantial revenue share. Companies are embracing the trend of offering varied reagents that simplify workflow process
Use of predictive biomarkers for diagnosis and monitoring take cancer eradication a step further. Moreover, organizations and programs such as the National Biomarker Development Alliance (NBDA) are actively participating in development of novel biomarkers for cancer diagnosis
Growing interest of pharmaceutical and biotechnology companies in genomics is expected to drive growth of the genomics market in the forthcoming years
Asia Pacific is anticipated to display the maximum potential and an become an emerging market for genomics. It is anticipated to register the fastest CAGR of 10.4% over the forecast period
Major players include BGI; Agilent Technologies; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc; Foundation Medicine, Inc, 23andMe, Inc, Danaher, Illumina, Inc; Pacific Biosciences; Oxford Nanopore Technologies.; F. Hoffmann-La Roche Ltd., and Myriad Genetics, Inc.

About Grand View Research

Vaccine Contract Manufacturing Market Is Poised To Reach $4.0 Billion By 2025

The global vaccine contract manufacturing market size is expected to reach USD 4.0 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a 9.3% CAGR during the forecast period. The market is anticipated to witness significant growth over the coming years thanks to rising demand for vaccine development from the private sector as well as governments in industrialized and developing countries.

Vaccine contract services offer cost-saving benefits to their clients. They also help save time in operations and management of a production and research facility. These advantages associated with Contract Manufacturing Organizations (CMOs) are expected to benefit emerging players, start-ups, and small players who lack adequate facilities and resources required for vaccine development.

Increase in pricing pressure, regulatory challenges, and patent expiration in recent times are expected to adversely impact the market. Contract services are considered “strategic competitive weapons” among vaccine manufacturers as they help overcome the aforementioned issues.

A number of international healthcare organizations are engaged in estimating and predicting the quantity of goods as well as financial need required for conducting immunization programs. Some of the factors considered for this estimation are quantity of vaccines, estimated time of delivery, product type, and vial size. Participation of international healthcare organizations in vaccination programs is expected to positively influence the growth of contract manufacturers.

Access Full Insights: https://www.grandviewresearch.com/industry-analysis/vaccine-contract-manufacturing-market

Further key findings from the report suggest:

Contract services for development of attenuated vaccines accounted for the major share in the market based on vaccine type. This can be attributed to the fact that these vaccines offer immunity for a lifetime with only one or two doses
DNA vaccines form the fastest-growing segment by type, with several kinds already being tested on humans
Based on workflow, downstream processing dominated the market mainly due to the necessity of mature and reliable biotechnology tools for product recovery. Various research initiatives in the space are also contributing in advancing downstream workflows
By application, contract services for the development of human-use vaccines held the largest share owing to their high adoption to develop vaccines against influenza and other illnesses
Lonza; IDT Biologika GmbH; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; and Merck KGaA are some of the major players offering services for vaccine development.

About Grand View Research

Arthroscopy Market Projected To Reach $6.34 Billion By 2024

The Global arthroscopy market is anticipated to reach USD 6.34 billion by 2024, according to a new report by Grand View Research, Inc. Increasing geriatric population base and rising obesity levels are the major factors driving the growth.

Rising medical tourism, cost efficiency and faster recovery rate are some of the factors resulting in increased adoption. As a result, demand for arthroscopy is increasing, since it’s used in the diagnosis of joint conditions. In addition, constant decline in the price coupled with reimbursement coverage is spurring the adoption of arthroscopy in the treatment of injuries.

Presently, the sector is fragmented in nature with presence of many players competing with each other. The key players are implementing mergers and acquisition strategies to strengthen their position by the expansion of customer base and reduce the number of competing players.

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/arthroscopy-market

Further key findings from the study suggest:

Arthroscopic implant segment dominated globally and is estimated to remain dominant throughout the forecast period. Increasing adoption of implants for diagnosis is mainly driving the growth of the segment.
The arthroscopic visualization systems are anticipated to witness strong demand during the forecast period due to their ability to provide clear high definition resolution of internal organs.
The demand for Fluid Management Systems is going to increase considerably during the forecast period with new products entering the sector especially in emerging countries such as Brazil, Mexico and South Africa.
The key players have faced challenges due to severe pricing pressures and stringent regulatory guidelines. The existing companies are finding it difficult to garner strong revenues.
Rising demand for minimally surgeries is also supporting the revenue growth since arthroscopy supports the same.
China, India, Brazil and South Africa are anticipated to register significant growth over the forecast period owing to rising patient awareness related to arthroscopy, presence of largest pool of geriatric population prone to injuries and the surging prevalence of chronic diseases such as osteoarthritis, bone tumor and rheumatoid arthritis.
Lenient regulatory approval procedures in Asia Pacific are offering easy entry of the new products in the region.
Some of the key players operating at the global level include but are not limited to ConMed Corporation, Arthrex Inc, Stryker Corporation, Olympus Corporation, Smith & Nephew plc, DePuy Synthes and Zimmer Biomet.
North America dominated the global scenario with regional share of over 40.0% in 2015. Technological advancements, such as introduction of advanced visualization systems, primarily led to highest revenue generation in the region. Visualization systems help in minimally invasive surgery by providing 3D image of the joint.
In addition, favorable reimbursement structure, presence of large target patient population and well defined regulatory framework are few factors that are positively affecting the market.

About Grand View Research

Biomarkers Market Is Estimated To Generate $118 Billion By 2026

The global biomarkers market size is expected to reach over USD 118 billion by 2026, according to a new study by Grand View Research Inc. It is projected to expand at a CAGR of 13.7% during the forecast period. Technological advancements, high consumer awareness, and increasing funds for research and development (R&D) activities are collectively propelling the market growth.

Drug discovery was estimated to be one of the highest revenue generating segments of the market. Pharmaceutical companies are undertaking extensive R&D initiatives to develop targeted therapeutics. Coordinated research efforts on biomarker development is a rising trend among commercial R&D organizations, academic research institutions, federal government biomedical regulatory and research agencies, and nonprofitable health foundations.

North America led the biomarker market in 2018, driven by high disease prevalence, proactive governmnet initiatives, and substantial demand for personalized medicines. North America is anticipated to retain its leading position throughout the forecast period. Asia Pacific is expected to witness the fastest regional growth, spearheaded by India.

Some key players operating in the biomarkers market include F. Hoffmann-La Roche Ltd.; Abbott.; Epigenomics AG; Agilent Technologies, Inc.; Johnson & Johnson Services, Inc; Siemens Healthcare Private Limited; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; and Qiagen. Key players are developing novel kits and therapies or drugs to target population in the areas with high unmet clinical needs.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/biomarkers-industry

Further key findings from the study suggest:

Safety biomarkers held the largest market share of over 42% in 2018 due to reduction in drug attrition and increasing awareness of routine healthcare checkups
Validation biomarkers is estimated to be one of the fastest growing segments
Personalized medicine is estimated to grow at a CAGR of 15.0% over the forecast period owing to growing consumer awareness
Cancer held the largest market share in 2018, driven by an increase in global prevalence of cancer and the presence of a strong pipeline of drugs
Cardiovascular diseases is projected to be the fastest growing segment throughout the forecast period, supported by sedentary lifestyles and growing obese population.

About Grand View Research

Hemoglobinopathies Market Worth $12.6 Billion By 2026 | Top Companies Are Gamida Cell & Alnylam Pharmaceuticals; Sanofi

The global hemoglobinopathies market size is expected to reach USD 12.6 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.2% during the forecast period.

Rising prevalence of hemoglobin disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E is estimated to be a high impact rendering driver for the market. According to the World Health Organization (WHO), hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant hemoglobin variation.

Prevalence of hemoglobinopathies is high in low-income countries from regions, such as Sub-Saharan region and South-east Asia. 85% of the affected population in U.S. and Europe has ancestral base in these regions.

Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Sickle Cell Disease Coalition (SCDC) was founded by The American Society of Hematology (ASH) in 2016 to promote awareness for the condition and enhance outcomes for individuals.

Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are some of the key factors contributing to the increase in target population in low-income regions such as South-east Asia, Mediterranean basin, and Africa.

North America led the overall hemoglobinopathies market in terms of revenue in 2018. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing, are the factors attributed to the growth.

Asia Pacific is expected to witness lucrative growth over the forecast period owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives for hemoglobinopathies is likely to further boost the growth.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/hemoglobinopathies-market

Further key findings from the report suggest:

SCD segment held the largest market share in 2018 owing to rising prevalence of sickle cell disease and presence of strong product pipeline such as LentiGlobin
Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. Increasing awareness coupled with rising government programs is anticipated to enhance the usage rates for diagnostic tests pertaining to SCD
Pre-implant genetic diagnosis is estimated to witness lucrative CAGR of over 8.0% during the forecast period owing to rising awareness levels among the population and increasing healthcare expenditure
Blood transfusion was the largest therapy segment for hemoglobinopathies, owing to high acceptance of this treatment option and significant success rate
Key market players include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation

About Grand View Research

Ingestible Sensors Market Is Poised To Reach $1.99 Billion By 2024

The global ingestible sensors market size is expected to reach USD 1.99 billion by 2024, according to a new report by Grand View Research, Inc. The market is anticipated to register a strong CAGR of 19.1% over the forecast period. Growing need for medical adherence and real-time monitoring of health along with rising prevalence of chronic diseases are some of the factors driving the market growth. Patient compliance is another key factor boosting the usage of ingestible sensors.

Simple procedure, user convenience, and minimal side effects are the factors leading to increased medical adherence by patients of all age groups, thus, driving the market growth. Increasing cases of chronic diseases, such as diabetes, hypertension, and cancer have also led to the market expansion. According to the International Diabetes Federation (IDF), around 642 million people across the world are projected to have diabetes by 2040.

In addition, growing geriatric population is also leading to numerous health issues, which is further raising the incidences of such chronic diseases. With technological advancements, ingestible sensors are growing rapidly in the field of digital medicine. Thus, it is anticipated to grow further in applications like customized drug delivery. However, costly raw materials and techniques for the development and design of this product may impede the market growth.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/ingestible-sensors-market

Further key findings from the study suggest:

In 2016, temperature sensors led the market owing to their benefits in diagnosing and treating heat-related illness, particularly among athletes
Image sensors are projected to show a significant growth over the forecast period due to their accuracy and clear images for the diagnosis of critical diseases
Sensors held the largest market share in 2016 amongst the component segment due to the advanced and expensive technology used in these devices
Medical segment accounted for the largest market share in 2016 owing to huge scope of application for ingestible sensors in drug delivery and patient monitoring
North America held the largest market revenue in 2016 due to high awareness levels regarding the availability of advanced technologies
Asia Pacific is anticipated to register a significant CAGR over the forecast period on account of increasing geriatric population and prevalence of chronic diseases, especially in the developing countries
Some of the key companies in the market are Proteus Digital Healthcare; CapsoVision Inc.; Given Imaging Ltd; Olympus Corporation; Medimetrics Inc.; HQ Inc.; MC10 Inc.; and Microchips Biotech Inc.

About Grand View Research

Latest Market Research Updates

Medical Image Analysis Software Market Is Estimated To Reach $4.51 Billion By 2024

Diabetic Retinopathy Market Is Poised To Reach $10.08 Billion By 2025

Diabetes Devices Market Is Expected To Surpass Mark Of $35.5 Billion By 2024

Dental 3D Printing Market Is Poised To Reach $9.78 Billion By 2025

Coronary Stents Market Is Poised To Reach $15.18 Billion By 2024

3D Bioprinting Market Is Poised To Reach $4.1 Billion By 2026

Stem Cell Market Total Revenue Would Be $15.63 Billion By 2025

Biotechnology Market Is Estimated To Generate Revenue Of $727.1 Billion By 2025

Genomics Market Is Projected To Reach $27.61 Billion By 2025

Vaccine Contract Manufacturing Market Is Poised To Reach $4.0 Billion By 2025

Arthroscopy Market Projected To Reach $6.34 Billion By 2024

Biomarkers Market Is Estimated To Generate $118 Billion By 2026

Hemoglobinopathies Market Worth $12.6 Billion By 2026 | Top Companies Are Gamida Cell & Alnylam Pharmaceuticals; Sanofi

Ingestible Sensors Market Is Poised To Reach $1.99 Billion By 2024

mHealth Apps Market Is Projected To Reach $236.0 Billion By 2026

Report Abuse

Labels